Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety

doi:10.21037/jtd-22-1192

	Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety
	Shao, Lan 1; Lou, Guangyuan 1,2
刊名	JOURNAL OF THORACIC DISEASE
	2022-09-15
关键词	Neoadjuvant immunotherapy immune-checkpoint inhibitors non-small cell lung cancer (NSCLC)
ISSN号	2072-1439
DOI	10.21037/jtd-22-1192
通讯作者	Lou, Guangyuan(lougy@zjcc.org.cn)
英文摘要	Background and Objective: Immune checkpoint inhibitors and immunotherapy have been shown to improve survival rates, especially in non-small cell lung cancer (NSCLC) patients. More recently, several trials have evaluated the clinical roles of immunotherapy as neoadjuvant settings for NSCLC. There trials suggested that neoadjuvant immunotherapy may effectively reduce the risk of the local recurrence and metastasis of cancer, and significantly improved overall survival and cure rates. Here we conducted a review to summarize the possible mechanism, clinical development, and research progress of neoadjuvant immunotherapy in NSCLC.Methods: Relevant articles for this review were retrieved from Google Scholar, Clinicaltrials.gov., and PubMed using the terms "non-small-cell lung cancer", "NSCLC", "neoadjuvant", "immunotherapy", "immune checkpoint inhibitors", "mechanisms", and "toxicity". The primary focus was placed on clinical studies and conference abstracts measuring the safety and efficacy of neoadjuvant immunotherapy in NSCLC until May 2022.Key Content and Findings: After reviewing the preclinical and clinical trial, the preclinical study showed that neoadjuvant immune checkpoint inhibitor promotes antitumor immunity through the enhancement of T cell effector function and the induction of long-term memory. The initial results of preliminary early-phase trials suggested that neoadjuvant immunotherapy is a promising therapeutic strategy for resectable NSCLC patients, with long-term response and modest toxicity, many of these regimens are currently being evaluated by randomized phase III trials. In addition, the major pathologic response of neoadjuvant immunotherapy ranged up to 45% in these studies when used alone, and up to around 83-86% when used in combination with chemotherapy, therefore it has been seen as a rather potent tumor debulking agent.Conclusions: Neoadjuvant immunotherapy has been shown to be a novel integral component of NSCLC care. However, there are also several research questions that requires further investigation, such as the side effects, the optimally treated patients, and the time of preoperative immunotherapy.
资助项目	Medical and Health Science and Technology Program of Zhejiang Province, China[2018KY023] ; Medical and Health Science and Technology Program of Zhejiang Province, China[2022KY644]
WOS关键词	VINORELBINE PLUS CISPLATIN ; SINGLE-ARM ; OPEN-LABEL ; PHASE-III ; CHEMOTHERAPY ; MULTICENTER ; NSCLC ; ATEZOLIZUMAB ; DURVALUMAB ; IB
WOS研究方向	Respiratory System
语种	英语
出版者	AME PUBLISHING COMPANY
WOS记录号	WOS:000857014700001
资助机构	Medical and Health Science and Technology Program of Zhejiang Province, China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128996]
专题	中国科学院合肥物质科学研究院
通讯作者	Lou, Guangyuan
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Chinese Acad Sci,Canc Hosp,Dept Med Oncol, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Chinese Acad Sci,Canc Hosp,Dept Med Oncol, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Shao, Lan,Lou, Guangyuan. Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety[J]. JOURNAL OF THORACIC DISEASE,2022.
APA	Shao, Lan,&Lou, Guangyuan.(2022).Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety.JOURNAL OF THORACIC DISEASE.
MLA	Shao, Lan,et al."Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety".JOURNAL OF THORACIC DISEASE (2022).